PMID- 38317032 OWN - NLM STAT- MEDLINE DCOM- 20240207 LR - 20240207 IS - 1119-3077 (Print) VI - 27 IP - 1 DP - 2024 Jan 1 TI - Prevalence of HLA B27 in Patients Diagnosed with Ankylosing Spondylitis (AS) in Diyarbakir, Southeastern Region of Turkey. PG - 29-34 LID - 10.4103/njcp.njcp_258_23 [doi] AB - AIM: The research to be conducted on human leukocyte antigen (HLA)-B27 in patients diagnosed with ankylosing spondylitis (AS) in Diyarbakir between 2019-2021 is to contribute to the understanding of the prevalence and effect of this genetic marker in the local population. As a researcher working on HLA-B27 and AS, our focus is to research the following. HLA-B27 Prevalence: To determine the prevalence of HLA-B27 in patients diagnosed with AS during the specified period in Diyarbakir. This information can provide insight into the genetic factors associated with the disease in the local population. Disease Severity: Investigate the relationship between HLA-B27 positivity and severity of AS symptoms. To examine factors such as disease progression, pain levels, functional impairment, and quality of life in HLA-B27 positive patients compared to HLA-B27 negative patients. By Genetic Associations: To enable the discovery of potential genetic relationships between HLA-B27 and other genetic markers known to be associated with AS. To investigate whether there are any specific genetic variants associated with HLA-B27 that contribute to disease susceptibility or severity. Researchers: We recommend considering the following approaches to generate knowledge on this topic globally: Literature Review: Conducting a comprehensive review of the available scientific literature on HLA-B27 and AS. It is to describe relevant studies conducted globally and summarize their findings to provide a broader understanding of the subject. Collaboration and Data Sharing: To encourage cooperation with researchers from other regions or countries doing similar studies on HLA-B27 and ASs. By sharing our data and collaborating on analysis, we can improve the global perspective and generalizability of your findings. International Conferences and Journals: Presenting our research findings at international conferences focusing on rheumatology, genetics or related fields. To disseminate our findings globally is to submit your research articles to reputable journals specializing in AS or genetic studies. Online Platforms: Using online platforms such as Researchgate.net, academia.edu or social media networks to share our research findings, connect with other researchers in the field and participate in discussions on a global scale. By using these fields, it is possible to contribute to the global knowledge and understanding of the relationship between HLA-B27 and AS. It is also to obtain insights from studies carried out in other regions. MATERIALS AND METHODS: 198 (104 male and 94 female) patients who applied to Dicle University Faculty of Medicine Physical Therapy and Rehabilitation Clinic with AS symptoms between 2019-2021 and were referred to Dicle University Medical Biology and Genetics Department for evaluation. HLA-B27 positivity was included in our study as a case group. As the control group, 50 people (25 males, 25 females) were selected among the unrelated people who applied to our laboratory to be a bone marrow donor. In both groups, DNA isolation was performed from peripheral blood using the salt precipitation method. Rotar Gene Q device was used for real-time PCR analysis. As a statistical method in analysis; The prevalences of the variables of interest were calculated. The lower and upper limits of 95% were determined as the confidence interval. According to the presence of HLA 27 positivity, the mean of ESR, CRP, and age variables were compared. Mann-Whitney U test was used due to the small number of subjects. Also, correlations between ESR and CRP were calculated. Spearman rho correlation statistics were used as a statistical method. Analyzed. RESULT: Radiological examinations and laboratory tests were performed on 198 patients with suspicion AS and 50 healthy control group of 248 subjects. The prevalence of those with a definite diagnosis of AS was calculated as statistical analysis recalculated 20.16 (95% CI: 0.76-0.9552). The prevalence of HLA-B27 in 50 patients diagnosed with AS as a result of radiological examinations and laboratory tests was calculated as 92%. CONCLUSION: Our study is the first study covering the province of Diyarbakir in the Southeastern Anatolia Region, which we think will contribute to the literature in the evaluation of HLA-B27 positivity in AS patients. The prevalence of HLA-B27 in our region is higher than the prevalence in Turkey. CI - Copyright (c) 2024 Copyright: (c) 2024 Nigerian Journal of Clinical Practice. FAU - Oral, D AU - Oral D AD - Department of Medical Biology and Genetics, Dicle University, Diyarbakir, Turkey. FAU - Erdal, G G AU - Erdal GG AD - Department of Medical Biology and Genetics, Dicle University, Diyarbakir, Turkey. FAU - Tekes, S AU - Tekes S AD - Department of Medical Biology and Genetics, Dicle University, Diyarbakir, Turkey. FAU - Yucel, I AU - Yucel I AD - Department of Medical Biology and Genetics, Dicle University, Diyarbakir, Turkey. FAU - Em, S AU - Em S AD - Department of Physical Therapy and Rehabilitation, Dicle University, Diyarbakir, Turkey. LA - eng PT - Journal Article PT - Review DEP - 20240205 PL - India TA - Niger J Clin Pract JT - Nigerian journal of clinical practice JID - 101150032 RN - 0 (HLA-B27 Antigen) RN - 0 (Genetic Markers) SB - IM MH - Humans MH - Male MH - Female MH - *Spondylitis, Ankylosing/epidemiology/genetics/diagnosis MH - HLA-B27 Antigen/genetics MH - Prevalence MH - Turkey/epidemiology MH - Quality of Life MH - Genetic Predisposition to Disease MH - Genetic Markers EDAT- 2024/02/06 00:42 MHDA- 2024/02/07 06:42 CRDT- 2024/02/05 23:41 PHST- 2023/04/05 00:00 [received] PHST- 2023/07/23 00:00 [accepted] PHST- 2024/02/07 06:42 [medline] PHST- 2024/02/06 00:42 [pubmed] PHST- 2024/02/05 23:41 [entrez] AID - 01253091-202401000-00005 [pii] AID - 10.4103/njcp.njcp_258_23 [doi] PST - ppublish SO - Niger J Clin Pract. 2024 Jan 1;27(1):29-34. doi: 10.4103/njcp.njcp_258_23. Epub 2024 Feb 5.